Addex Therapeutics Ltd (ADXN)

Currency in CHF
0.022
0.000(0.00%)
Closed·
Trading near 52-week Low
ADXN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0180.022
52 wk Range
0.0180.069
Key Statistics
Bid/Ask
0.026 / 0.022
Prev. Close
0.022
Open
0.022
Day's Range
0.018-0.022
52 wk Range
0.018-0.069
Volume
1.6M
Average Volume (3m)
814.42K
1-Year Change
-64.6497%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADXN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Addex Therapeutics Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Earnings

Latest Release
Sep 28, 2026
EPS / Forecast
-0.01 / --
Revenue / Forecast
9.95K / --
EPS Revisions
Last 90 days

ADXN Income Statement

Compare ADXN to Peers and Sector

Metrics to compare
ADXN
Peers
Sector
Relationship
P/E Ratio
−0.4x13.1x−0.3x
PEG Ratio
0.160.020.00
Price/Book
1.4x2.3x2.6x
Price / LTM Sales
31.6x2.1x3.0x
Upside (Analyst Target)
-40.9%58.6%
Fair Value Upside
Unlock2.4%8.4%Unlock

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.04M1.71%45.33K
Other Institutional Investors
5.76K0.00%127.87
Public Companies & Retail Investors
117.27M98.28%2.60M
Total
119.32M100.00%2.65M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
UBS Asset Management AG1.64%1,957,69143
UBS (CH) Index Fund - Equities Switzerland Small & Mid0.37%443,48710

People Also Watch

5.92
CNTL
+2.07%
48.50
GURN
-15.51%
12.81
DOCM
+1.99%
1.23
KUD
-3.15%
66.80
BSLN
-1.47%

FAQ

What Is the Addex Therapeutics Ltd (ADXN) Stock Price Today?

The Addex Therapeutics Ltd stock price today is 0.022 CHF.

What Stock Exchange Does Addex Therapeutics Ltd Trade On?

Addex Therapeutics Ltd is listed and trades on the Switzerland Stock Exchange.

What Is the Stock Symbol for Addex Therapeutics Ltd?

The stock symbol for Addex Therapeutics Ltd is "ADXN."

What Is the Addex Therapeutics Ltd Market Cap?

As of today, Addex Therapeutics Ltd market cap is 2.650M CHF.

What Is Addex Therapeutics Ltd's Earnings Per Share (TTM)?

The Addex Therapeutics Ltd EPS (TTM) is -0.063.

When Is the Next Addex Therapeutics Ltd Earnings Date?

Addex Therapeutics Ltd will release its next earnings report on Nov 09, 2026.

From a Technical Analysis Perspective, Is ADXN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Addex Therapeutics Ltd Stock Split?

Addex Therapeutics Ltd has split 0 times.

How Many Employees Does Addex Therapeutics Ltd Have?

Addex Therapeutics Ltd has 3 employees.

What is the current trading status of Addex Therapeutics Ltd (ADXN)?

As of Oct 03, 2026, Addex Therapeutics Ltd (ADXN) is trading at a price of 0.022 CHF, with a previous close of 0.022 CHF. The stock has fluctuated within a day range of 0.018 CHF to 0.022 CHF, while its 52-week range spans from 0.018 CHF to 0.069 CHF.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.